Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0
STEP I: Patients must not have grade 2 or higher peripheral neuropathy by Common Terminology Criteria for Adverse Events (CTCAE) 4.0
Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0) in patients with no prior oxaliplatin therapy
Patients must not have Common Terminology Criteria for Adverse Events (CTCAE) >= grade 2 neuropathy (cranial, motor or sensory) within 14 days prior to registration
Symptomatic peripheral neuropathy >= grade 2 Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 (for participants receiving docetaxel only)
Peripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
Pre-existing, clinically significant peripheral neuropathy, defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher neurosensory or neuromotor toxicity, regardless of etiology
Neurologic function: neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Has pre-existing peripheral neuropathy that is ? Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version 4 criteria.
Subjects must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
STUDY TREATMENT: Peripheral neuropathy less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1.
Patients with peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 2
Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1
No Common Terminology Criteria for Adverse Events (CTCAE) v4 grade > 2 neuropathy
Nervous system disorder (i.e., paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0
Peripheral neuropathy ? grade 2 (Common Terminology Criteria for Adverse Events CTCAE)
Pre-existing peripheral neuropathy > grade 1 (using Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.3 criteria)
Neuropathy (sensory and motor) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1
Must have =< grade 1 pre-existing peripheral neuropathy (as per Common Terminology Criteria for Adverse Events [CTCAE])
Pre-existing motor or sensory neurotoxicity greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Grade 3 or worse peripheral neuropathy as defined by Common Terminology Criteria for Adverse Events (CTCAE) v4.1
Peripheral neuropathy =< Common Terminology Criteria for Adverse Events (CTCAE) grade 2
Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.0) grade 1 acceptable
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Pre-existing peripheral neuropathy that is >= grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 criteria
Nervous system disorder (paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Patients with =< grade 1 peripheral neuropathy are eligible for this trial using the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0, regardless of use of therapy for neuropathy including gabapentin
Presence of CTCAE (Common Terminology Criteria for Adverse Events) grade ? 2 peripheral neuropathy.
Peripheral neuropathy of Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade >= 2
Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0
Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0. In CTCAE version 4.0 grade 2 sensory neuropathy is defined as â€œmoderate symptoms; limiting instrumental activities of daily living (ADLs).
Pre-existing peripheral neuropathy that is >= grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) v4 criteria
Sensory peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 1
Patients with peripheral neuropathy >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 are ineligible
Sensory peripheral neuropathy =< grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] version [v.] 4.0)
Patients with pre-treatment peripheral neuropathy greater than grade 1 per the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 will be excluded
Symptomatic peripheral neuropathy > grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) criteria
Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
Pre-existing peripheral neuropathy, if present, must be < grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)
Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events v4.0).
For Cohort B: Has peripheral neuropathy Common Terminology Criteria for Adverse Events ?2 except due to trauma
Peripheral neuropathy >= grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] version [v]4)
Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1
Presence of peripheral neuropathy ? Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Peripheral neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher
Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0; in CTCAE version 4.0 grade 2 sensory neuropathy is defined as \moderate symptoms; limiting instrumental activities of daily living (ADLs)\
Neuropathy (sensory) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1
Patients with peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 2
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Patients with =< grade 1 peripheral neuropathy are eligible for this trial using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0, regardless of use of therapy for neuropathy including gabapentin
Patients must not have >= grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
< grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Presence of peripheral neuropathy ? Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
Patients with pre-existing neuropathy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (motor or sensory)
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])
Preexisting peripheral neuropathy of grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events v 4.0)
Patients must not have grade 2 or greater pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE] 4.0)
Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Criteria for Adverse Events (CTCAE) v4.0).
Patients must have < grade 2 pre-existing peripheral neuropathy per Common Terminology Criteria for Adverse Events (CTCAE)
Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0; in CTCAE version 4.0 grade 2 sensory neuropathy is defined as \moderate symptoms; limiting instrumental activities of daily living (ADLs)\
Current peripheral neuropathy greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 except due to trauma
Patients must have =< grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE] v4.0)
Patients with pre-existing peripheral neuropathy must have < grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] 4.0) at the time of registration
Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events 4.03 [CTCAE 4.03])
